The Brighterside of News on MSN
First human trial of a CRISPR-based treatment significantly lowered cholesterol and triglycerides
A quiet hope has started to grow among people living with stubborn cholesterol problems as researchers report early success ...
Since the middle of the 20th century, antibiotics have been among the greatest successes in medicine. They save millions of ...
Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced mu ...
Immunometabolism have advanced the understanding of dynamic interplay between metabolic pathways and immune responses.
Sharpen your Mains answer-writing skills with GS-3 questions by following the thought process. Do not miss points to ponder ...
Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...
A new gene therapy shows promise in controlling cholesterol by lowering bad LDL levels, potentially reducing the risk of ...
Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...
A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects ...
Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 ...
Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results